Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$1.20
EPS est.
$0.79
EPS surprise
+52.28%
1-day move
+2.59%
BioMarin Pharmaceutical's strong EPS performance exceeded expectations, contributing to a 2.59% increase in stock price. However, revenue figures were not disclosed, leaving some uncertainty about overall financial health. Investors may view the EPS beat as a positive sign, but the lack of revenue data and guidance could lead to cautious sentiment going forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.20 | $0.95 | +52.28% |
| Revenue | — | $932M | — |
No transcript is on record, and the analysis is based solely on numerical results.
BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing innovative therapies for serious genetic diseases. With a market cap of $13 billion, it plays a significant role in the healthcare sector, particularly in rare disease treatment, which is a growing area of interest for investors.
Last quarter
In Q1-2026, BioMarin reported an EPS of $0.76, slightly below the estimate of $0.78, resulting in a 2.59% increase in stock price the next day. The company continues to navigate challenges in meeting revenue expectations.
EPS beat streak
1Q
EPS beat rate
75%
Avg EPS surprise
+104.31%
Avg 1-day reaction
+0.39%
Analysts expect BioMarin to report an EPS of $0.95 and revenue of $932 million for Q2-2026, reflecting cautious optimism in the market. The company has a strong track record of beating EPS estimates, with a 75% success rate in the last eight quarters.
Bull case
If BioMarin exceeds the EPS estimate, it could signal strong demand for its products and effective cost management, potentially leading to a positive stock reaction.
Bear case
Conversely, if the company misses its EPS target, it could raise concerns about its growth prospects and market competition, leading to a negative impact on the stock price.
Key metrics to watch
EPS
$0.95Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$932MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will BioMarin achieve an EPS of $0.95 or higher?
This figure is critical as it will indicate the company's ability to manage costs and drive sales, influencing investor confidence.
Q2
What are the revenue expectations for the upcoming quarter?
Revenue performance will provide insight into market demand for BioMarin's products and its competitive positioning in the biotechnology sector.
—
Est. EPS
$1.89
Est. Rev
$705M
Impl. Move
±12.5%
Why consensus could be wrong
The Street may be underestimating the potential for BioMarin to exceed EPS expectations based on its historical performance and product pipeline advancements.
Supporting evidence
BioMarin has a 75% success rate in beating EPS estimates over the last eight quarters.
Options pricing suggests a significant move, indicating that traders expect volatility that may not align with consensus.
Recent product launches have shown strong market demand, which may not be fully reflected in current estimates.
Key risk
If the company reports an EPS significantly above $0.95, it could shift market sentiment positively.
Pre-commit to what would confirm each case.
The market is closely watching BioMarin's ability to meet or exceed earnings expectations, which could significantly affect its stock price.
Bull confirmed if
An EPS of $1.00 or higher would confirm strong operational performance and market demand.
Bear confirmed if
An EPS below $0.80 would raise concerns about the company's growth trajectory.
What the market is pricing for the move.
Implied Move
±15.32%
Historical Avg
±2.1%
The options market is pricing in a significant move of over 15%, indicating heightened uncertainty around the earnings report.
Options are pricing ±15.3% while BMRN has averaged ±2.1% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
42.3%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
103.53%
of float
Insider
0.34%
of float
Holders
757
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
20,445,212 sh · $1.1B
10.56%
3.2%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If BioMarin beats expectations, history suggests the stock could see a modest increase, confirming the company's growth narrative.
In line / cautious
If results are in line with expectations, the stock may experience minimal movement as investors await further guidance.
Miss
A miss could lead to a decline in stock price, with historical patterns indicating an average drop of around 0.37%.
The lines on the call that would change the story.
Dodge & Cox Inc.
14,844,930 sh · $819.4M
7.67%
1.9%
Primecap Management Company
14,190,183 sh · $783.3M
7.33%
-0.0%
Vanguard Capital Management LLC
8,743,633 sh · $482.6M
4.52%
1.2%
Vanguard Portfolio Management LLC
8,648,678 sh · $477.4M
4.47%
4.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.